Patents by Inventor Cécile Bonnafous

Cécile Bonnafous has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of peripheral T cell lymphoma
    Patent number: 11999784
    Abstract: The present disclosure relates to methods for the treatment, prevention and diagnosis of peripheral T-cell lymphoma using compounds that specifically bind NKp46. Included in particular are compounds that bind NKp46 and deplete tumor cells that express NKp46 at their surface, and pharmaceutical compositions comprising the same. The disclosure also relates to the use of antibodies that specifically bind NKp46 in diagnostic and theranostic assays in the detection and treatment of peripheral T-cell lymphoma.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: June 4, 2024
    Assignee: INNATE PHARMA
    Inventors: Cécile Bonnafous, Hélène Sicard, Renaud Buffet, Mathieu Blery
  • IMMUNOHISTOCHEMISTRY METHODS AND KIR3DL2-SPECIFIC REAGENTS
    Publication number: 20240117042
    Abstract: The present invention relates to antibodies and methods for detecting KIR3DL2 expression in paraffin-embedded tissue samples. Also provide are methods of making antibodies, antibody fragments, and derivatives thereof that specifically bind to their target antigen in paraffin-embedded tissue samples.
    Type: Application
    Filed: April 4, 2022
    Publication date: April 11, 2024
    Inventors: BENJAMIN ROSSI, STÉPHANIE CHANTEUX, ROMAIN REMARK, CÉCILE BONNAFOUS, CLARENCE DEFFAUD, THIBAUT PELAT
  • COMPOUND THAT SPECIFICALLY BINDS TO KIR3DL2 FOR USE IN THE TREATMENT OF PERIPHERAL T CELL LYMPHOMA
    Publication number: 20210363248
    Abstract: The present invention relates to methods for the treatment, prevention and diagnosis of peripheral T cell lymphoma using compounds that specifically bind KIR3DL2. The invention also relates to use of antibodies that specifically bind KIR3DL2 in diagnostic and theranostic assays in the detection and treatment of peripheral T cell lymphoma.
    Type: Application
    Filed: July 29, 2021
    Publication date: November 25, 2021
    Inventors: CÉCILE BONNAFOUS, HÉLÈNE SICARD, RENAUD BUFFET
  • Compound that specifically binds to KIR3DL2 for use in the treatment of peripheral T cell lymphoma
    Patent number: 11078275
    Abstract: The present invention relates to methods for the treatment, prevention and diagnosis of peripheral T cell lymphoma using compounds that specifically bind KIR3DL2. The invention also relates to use of antibodies that specifically bind KIR3DL2 in diagnostic and theranostic assays in the detection and treatment of peripheral T cell lymphoma.
    Type: Grant
    Filed: January 7, 2019
    Date of Patent: August 3, 2021
    Assignee: INNATE PHARMA
    Inventors: Cecile Bonnafous, Helene Sicard, Renaud Buffet
  • MICA BINDING AGENTS
    Publication number: 20200299380
    Abstract: The present invention relates to methods for the treatment of disorders mediated by MICA-expressing cells using antibodies, antibody fragments, and derivatives thereof that specifically bind MICA. The invention also relates to antibodies; cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; and pharmaceutical compositions comprising the same.
    Type: Application
    Filed: February 28, 2020
    Publication date: September 24, 2020
    Inventors: Mathieu Blery, Laurent Gauthier, Ivan Perrot, Cecile Bonnafous
  • Methods for detecting tissue infiltrating NK cells
    Patent number: 10736963
    Abstract: The present invention relates to methods for detecting and monitoring NK cells in paraffin-embedded tissue samples. Also provided are antibodies, antibody fragments, and derivatives thereof that specifically bind to NKp46 present on the surface of NK cells in paraffin-embedded tissue samples.
    Type: Grant
    Filed: July 4, 2016
    Date of Patent: August 11, 2020
    Assignee: INNATE PHARMA
    Inventors: Nadia Anceriz, Cecile Bonnafous, Arnaud Dujardin, Carine Paturel
  • Mica binding agents
    Patent number: 10577416
    Abstract: The present invention relates to methods for the treatment of disorders mediated by MICA-expressing cells using antibodies, antibody fragments, and derivatives thereof that specifically bind MICA. The invention also relates to antibodies; cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; and pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: March 3, 2020
    Assignee: Innate Pharma, S.A.
    Inventors: Mathieu Blery, Laurent Gauthier, Ivan Perrot, Cecile Bonnafous
  • Combination of anti-KIR and anti-CS1 antibodies to treat multiple myeloma
    Patent number: 10494433
    Abstract: Provided are methods for clinical treatment of multiple myeloma using an anti-KIR antibody in combination with an anti-CS 1 antibody.
    Type: Grant
    Filed: November 5, 2014
    Date of Patent: December 3, 2019
    Assignees: BRISTOL-MYERS SQUIBB COMPANY, Innate Pharma
    Inventors: Pascale Andre, Mathieu Blery, Cecile Bonnafous, Ashok K. Gupta, Luisa M. Salter-Cid, Michael Darron Robbins
  • TREATMENT OF PERIPHERAL T CELL LYMPHOMA
    Publication number: 20190315857
    Abstract: The present disclosure relates to methods for the treatment, prevention and diagnosis of peripheral T-cell lymphoma using compounds that specifically bind NKp46. Included in particular are compounds that bind NKp46 and deplete tumor cells that express NKp46 at their surface, and pharmaceutical compositions comprising the same. The disclosure also relates to the use of antibodies that specifically bind NKp46 in diagnostic and theranostic assays in the detection and treatment of peripheral T-cell lymphoma.
    Type: Application
    Filed: June 25, 2019
    Publication date: October 17, 2019
    Inventors: CÉCILE BONNAFOUS, HÉLÈNE SICARD, RENAUD BUFFET, MATHIEU BLERY
  • Treatment of peripheral T cell lymphoma
    Patent number: 10344087
    Abstract: The present disclosure relates to methods for the treatment, prevention and diagnosis of peripheral T-cell lymphoma using compounds that specifically bind NKp46. Included in particular are compounds that bind NKp46 and deplete tumor cells that express NKp46 at their surface, and pharmaceutical compositions comprising the same. The disclosure also relates to the use of antibodies that specifically bind NKp46 in diagnostic and theranostic assays in the detection and treatment of peripheral T-cell lymphoma.
    Type: Grant
    Filed: February 13, 2014
    Date of Patent: July 9, 2019
    Assignee: INNATE PHARMA
    Inventors: Cécile Bonnafous, Hélène Sicard, Renaud Buffet, Mathieu Blery
  • COMPOUND THAT SPECIFICALLY BINDS TO KIR3DL2 FOR USE IN THE TREATMENT OF PERIPHERAL T CELL LYMPHOMA
    Publication number: 20190127463
    Abstract: The present invention relates to methods for the treatment, prevention and diagnosis of peripheral T cell lymphoma using compounds that specifically bind KIR3DL2. The invention also relates to use of antibodies that specifically bind KIR3DL2 in diagnostic and theranostic assays in the detection and treatment of peripheral T cell lymphoma.
    Type: Application
    Filed: January 7, 2019
    Publication date: May 2, 2019
    Inventors: CECILE BONNAFOUS, HELENE SICARD, RENAUD BUFFET
  • Compound that specifically binds to KIR3DL2 for use in the treatment of peripheral T cell lymphoma
    Patent number: 10174112
    Abstract: The present invention relates to methods for the treatment, prevention and diagnosis of peripheral T cell lymphoma using compounds that specifically bind KIR3DL2. The invention also relates to use of antibodies that specifically bind KIR3DL2 in diagnostic and theranostic assays in the detection and treatment of peripheral T cell lymphoma.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: January 8, 2019
    Assignee: INNATE PHARMA
    Inventors: Cecile Bonnafous, Helene Sicard, Renaud Buffet
  • METHODS FOR DETECTING TISSUE INFILTRATING NK CELLS
    Publication number: 20180369373
    Abstract: The present invention relates to methods for detecting and monitoring NK cells in paraffin-embedded tissue samples. Also provided are antibodies, antibody fragments, and derivatives thereof that specifically bind to NKp46 present on the surface of NK cells in paraffin-embedded tissue samples.
    Type: Application
    Filed: July 4, 2016
    Publication date: December 27, 2018
    Inventors: NADIA ANCERIZ, CECILE BONNAFOUS, ARNAUD DUJARDIN, CARINE PATUREL
  • TLR3 binding agents
    Patent number: 9944712
    Abstract: Disclosed herein are anti-TLR3 antibodies as well as methods of making and using them. The antibodies are particularly adapted to the treatment of autoimmune or inflammatory diseases using anti-TLR3 antibodies.
    Type: Grant
    Filed: May 30, 2013
    Date of Patent: April 17, 2018
    Assignee: Innate Pharma
    Inventors: Cécile Bonnafous, Laurent Gauthier, Yannis Morel, Carine Paturel, Ivan Perrot
  • COMPOUND THAT SPECIFICALLY BINDS TO KIR3DL2 FOR USE IN THE TREATMENT OF PERIPHERAL T CELL LYMPHOMA
    Publication number: 20170298132
    Abstract: The present invention relates to methods for the treatment, prevention and diagnosis of peripheral T cell lymphoma using compounds that specifically bind KIR3DL2. The invention also relates to use of antibodies that specifically bind KIR3DL2 in diagnostic and theranostic assays in the detection and treatment of peripheral T cell lymphoma.
    Type: Application
    Filed: June 15, 2017
    Publication date: October 19, 2017
    Inventors: CECILE BONNAFOUS, HELENE SICARD, RENAUD BUFFET
  • COMBINATION OF ANTI-KIR AND ANTI-CS1 ANTIBODIES TO TREAT MULTIPLE MYELOMA
    Publication number: 20160257750
    Abstract: Provided are methods for clinical treatment of multiple myeloma using an anti-KIR antibody in combination with an anti-CS 1 antibody.
    Type: Application
    Filed: November 5, 2014
    Publication date: September 8, 2016
    Inventors: Pascale ANDRE, Mathieu BLERY, Cecile BONNAFOUS, Ashok K. GUPTA, Luisa M. SALTER-CID, Michael Darron ROBBINS
  • A COMPOUND THAT SPECIFICALLY BINDS TO KIR3DL2 FOR USE IN THE TREATMENT OF PERIPHERAL T CELL LYMPHOMA
    Publication number: 20160002345
    Abstract: The present disclosure relates to methods for the treatment, prevention and diagnostic of peripheral T cell lymphoma using compounds that specifically bind KIR3DL2. The disclosure also relates to use of antibodies that specifically bind KIR3DL2 in diagnostic and theranostic assays in the detection and treatment of peripheral T cell lymphoma.
    Type: Application
    Filed: February 20, 2014
    Publication date: January 7, 2016
    Inventors: CÉCILE BONNAFOUS, HÉLÈNE SICARD, RENAUD BUFFET
  • TREATMENT OF PERIPHERAL T CELL LYMPHOMA
    Publication number: 20150376274
    Abstract: The present disclosure relates to methods for the treatment, prevention and diagnostic of peripheral T cell lymphoma using compounds that specifically bind NKp46. Included in particular are compounds that bind NKp46 and deplete tumor cells that express at their surface NKp46, and pharmaceutical compositions comprising the same. The disclosure also relates to use of antibodies that specifically bind NKp46 in diagnostic and theranostic assays in the detection and treatment of peripheral T cell lymphoma.
    Type: Application
    Filed: February 13, 2014
    Publication date: December 31, 2015
    Inventors: CÉCILE BONNAFOUS, HÉLÉNE SICARD, RENAUD BUFFET, MATHIEU BLERY
  • MICA BINDING AGENTS
    Publication number: 20150191542
    Abstract: The present invention relates to methods for the treatment of disorders mediated by MICA-expressing cells using antibodies, antibody fragments, and derivatives thereof that specifically bind MICA. The invention also relates to antibodies; cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; and pharmaceutical compositions comprising the same.
    Type: Application
    Filed: February 7, 2013
    Publication date: July 9, 2015
    Inventors: Mathieu Blery, Laurent Gauthier, Ivan Perrot, Cecile Bonnafous
  • TLR3 BINDING AGENTS
    Publication number: 20150140000
    Abstract: Disclosed herein are anti-TLR3 antibodies as well as methods of making and using them. The antibodies are particularly adapted to the treatment of autoimmune or inflammatory diseases using anti-TLR3 antibodies.
    Type: Application
    Filed: May 30, 2013
    Publication date: May 21, 2015
    Inventors: Cécile Bonnafous, Laurent Gauthier, Yannis Morel, Carine Paturel, Ivan Perrot